vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) shares passed above its fifty day moving average during trading on Thursday following a better than expected earnings announcement. The stock has a fifty day moving average of $18.96 and traded as high as $22.41. vTv Therapeutics shares last traded at $22.41, with a volume of 5,654 shares traded.
The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.04).
Wall Street Analyst Weigh In
Several equities research analysts have commented on the company. StockNews.com initiated coverage on vTv Therapeutics in a research note on Wednesday, April 16th. They set a "sell" rating for the company. HC Wainwright began coverage on vTv Therapeutics in a report on Wednesday, April 9th. They issued a "buy" rating and a $36.00 price objective on the stock.
Check Out Our Latest Stock Report on VTVT
Institutional Trading of vTv Therapeutics
A number of large investors have recently modified their holdings of VTVT. Connective Capital Management LLC acquired a new position in shares of vTv Therapeutics in the 1st quarter worth approximately $162,000. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics in the fourth quarter worth $25,000. Finally, Geode Capital Management LLC grew its holdings in vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,327 shares during the last quarter. Institutional investors and hedge funds own 17.51% of the company's stock.
vTv Therapeutics Trading Down 3.0%
The firm has a market cap of $65.76 million, a price-to-earnings ratio of -4.55 and a beta of 0.77. The firm has a 50-day moving average of $19.34 and a two-hundred day moving average of $17.03.
About vTv Therapeutics
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Recommended Stories
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
